Clinical Trials Logo

Filter by:
NCT ID: NCT04056195 Completed - Clinical trials for Immune Thrombocytopenia

Study of Oral SKI-O-703, SYK Inhibitor, in Patients With Persistent and Chronic Immune Thrombocytopenia (ITP)

Start date: October 11, 2019
Phase: Phase 2
Study type: Interventional

Study in patients with persistent and chronic Immune Thrombocytopenia (ITP), who have failed to respond or relapsed after prior therapy, with a platelet count <30,000/µL. Patient will be randomly assigned in 2 groups with two dose levels of SKI-O-703 200mg BID, 400 mg BID, and placebo; administered orally twice a day.

NCT ID: NCT04054921 Completed - ß-thalassemia Clinical Trials

Safety Study for Beta Thalassemia Subjects on PTG-300

TRANSCEND
Start date: May 10, 2019
Phase: Phase 2
Study type: Interventional

In this study will investigate long term safety and use of the PTG-300 in Beta Thalassemia patients.

NCT ID: NCT04054193 Completed - Clinical trials for Chemotherapy-induced Nausea and Vomiting

Safety of a Three-Day Fosaprepitant Regimen for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Pediatric Participants (MK-0517-045)

Start date: September 9, 2019
Phase: Phase 4
Study type: Interventional

The purpose of this study is to evaluate the safety and tolerability of a 3-day intravenous (IV) fosaprepitant dimeglumine (MK-0517) regimen for the prevention of CINV in pediatric participants scheduled to receive emetogenic chemotherapy. Each participant was enrolled in Cycle 1 (on which the primary study objectives were based), consisting of the 3-day treatment cycle and 14 days of follow-up for a total of 17 days.

NCT ID: NCT04053881 Completed - Plaque Psoriasis Clinical Trials

A Study to Assess How Well Certolizumab Pegol Works in Patients With Moderate to Severe Plaque Psoriasis as Part of Routine Clinical Practice

CIMREAL
Start date: August 21, 2019
Phase:
Study type: Observational

The purpose of the study is to assess the effectiveness of certolizumab pegol in patients with moderate to severe plaque psoriasis as part of routine clinical practice.

NCT ID: NCT04053764 Completed - Clinical trials for Sickle Cell Disease (SCD)

Study Exploring the Effect of Crizanlizumab on Kidney Function in Patients With Chronic Kidney Disease Caused by Sickle Cell Disease

STEADFAST
Start date: December 10, 2019
Phase: Phase 2
Study type: Interventional

The goal of the study was to evaluate descriptively the effect of crizanlizumab + standard of care and standard of care alone on renal function in sickle cell disease patients ≥ 16 years with chronic kidney disease due to sickle cell nephropathy.

NCT ID: NCT04051515 Completed - Clinical trials for End Stage Renal Disease on Dialysis

Home-based vs Intradialysis Exercise Guided by Nursing Staff

HoBIDnurse
Start date: August 9, 2019
Phase: N/A
Study type: Interventional

Participants will be randomized either to home-based exercise or to intradialysis exercise guided by nurses of the renal unit. The programs will last 16 weeks. The intradialysis exercise consists of combined aerobic and resistance training exercise. The home-based exercise consists of resistance exercise and walking.

NCT ID: NCT04050020 Completed - Clinical trials for Erectile Dysfunction Due to Arterial Insufficiency

Platelet-rich Plasma (PRP) Injection for Treatment of Erectile Function

Start date: September 2, 2019
Phase: Phase 2/Phase 3
Study type: Interventional

The primary objective of the present study is to investigate and compare the treatment efficacy of PRP injection vs placebo treatment in men with mild-moderate vasculogenic ED, as measured by IIEF.The secondary objective of the present clinical trial is to study the adverse events and safety of the PRP injection treatment in vasculogenic ED patients

NCT ID: NCT04046809 Completed - Glaucoma Clinical Trials

Study of Neurotidine® Intake on Life Quality of Patients With Glaucoma

Start date: February 13, 2019
Phase: N/A
Study type: Interventional

The purpose for the study consists in the assessment of the role of Neurotidine® (citicoline oral solution) on the dopaminergic pathway and particularly its potential implications on psychophysical performance and quality of life. Other objectives are the assessment of the tolerability and safety of Neurotidine®.

NCT ID: NCT04045743 Completed - Clinical trials for Scleroderma, Systemic

The Benefit of Bermekimab in Patients With Systemic Sclerosis

Start date: July 19, 2019
Phase: Phase 2
Study type: Interventional

This is a proof-of concept RCT trying to generate evidence that inhibition of IL-1α through the administration of bermekimab may inhibit progression of SSc.

NCT ID: NCT04041284 Completed - Clinical trials for Major Depressive Disorder

A Study to Evaluate the Efficacy and Safety of Fremanezumab for Preventive Treatment of Migraine in Patients With Major Depressive Disorder

Start date: September 13, 2019
Phase: Phase 4
Study type: Interventional

The primary objective is to evaluate the efficacy of monthly 225 mg sc fremanezumab in adult participants with migraine and major depressive disorder (MDD) The secondary objectives are to evaluate the efficacy of monthly 225 mg sc of fremanezumab in adult participants with migraine and MDD on the reduction of MDD symptoms, responder rates in monthly migraine days, improving quality of life, improving disability, and the safety and tolerability of monthly 225 mg sc and quarterly 675 mg sc fremanezumab in adult participants with migraine and MDD. The total duration of participant participation in the study is planned to be approximately 28 weeks.